Journal
ANNALS OF HEMATOLOGY
Volume 97, Issue 10, Pages 1749-1755Publisher
SPRINGER
DOI: 10.1007/s00277-018-3463-x
Keywords
Pml; Leukemia; Mesenchymal stem cells; Niche
Categories
Funding
- Instituto Serrapilheira/Serra [1708-15285]
- Pro-reitoria de Pesquisa/Universidade Federal de Minas Gerais (PRPq/UFMG) [05/2016]
- National Institute of Science and Technology in Theranostics and Nanobiotechnology (CNPq/CAPES/FAPEMIG) [465669/2014-0]
- FAPEMIG [Rede Mineira de Engenharia de Tecidos e Terapia Celular (REMETTEC)] [RED-00570-16]
- FAPEMIG [RED-00313-16, RED-00282-16]
- National Institute of Health [1R01CA179072-01A1]
- American Cancer Society [124443-MRSG-13-121-01-CDD]
- NATIONAL CANCER INSTITUTE [R01CA179072] Funding Source: NIH RePORTER
Ask authors/readers for more resources
The dynamic interactions between leukemic cells and cells resident within the bone marrow microenvironment are vital for leukemia progression. The lack of detailed knowledge about the cellular and molecular mechanisms involved in this cross-talk restricts the design of effective treatments. Guarnerio et al. (2018) by using state-of-the-art techniques, including sophisticated Cre/loxP technologies in combination with leukemia mouse models, reveal that mesenchymal stem cells via promyelocytic leukemia protein (Pml) maintain leukemic cells in the bone marrow niche. Strikingly, genetic deletion of Pml in mesenchymal stem cells raised survival of leukemic mice under chemotherapeutic treatment. The emerging knowledge from this research provides a novel target in the bone marrow niche for therapeutic benefit in leukemia.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available